Good steps, at least for pharma: - Require better registration of clinical trials and automatic aggregation of results, as part of medical regulation - Make t

Good steps, at least for pharma: - Require better registration of clinical trials and automatic aggregation of results, as part of medical regulation - Make the clinical data submitted to the FDA (or equivalent agencies) public, or at least accessible to researchers. Currently, the data sent to journals is not the same set previously submitted to the FDA; it's been touched up to make it more suitable for publication. Another paper found that overall these papers show slightly more positive results than the corresponding FDA data does. (Dunno how they managed to get that data set.) Authors have their own specific justifications for this, but the overall trend is bad.